Kelly Lawrence W & Associates Inc. CA Purchases Shares of 470,785 Hims & Hers Health, Inc. (NYSE:HIMS)

Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 470,785 shares of the company's stock, valued at approximately $11,384,000. Hims & Hers Health comprises approximately 2.7% of Kelly Lawrence W & Associates Inc. CA's investment portfolio, making the stock its 15th largest holding. Kelly Lawrence W & Associates Inc. CA owned 0.22% of Hims & Hers Health at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HighTower Advisors LLC bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $207,000. MML Investors Services LLC purchased a new stake in Hims & Hers Health in the 3rd quarter valued at about $197,000. Barclays PLC increased its stake in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after buying an additional 27,231 shares during the period. Geode Capital Management LLC boosted its position in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Finally, Sanctuary Advisors LLC raised its stake in shares of Hims & Hers Health by 26.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock worth $480,000 after acquiring an additional 5,505 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

HIMS stock traded up $1.40 during trading hours on Wednesday, reaching $26.75. The stock had a trading volume of 22,002,418 shares, compared to its average volume of 15,511,619. The stock has a 50-day simple moving average of $36.17 and a 200 day simple moving average of $30.81. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The stock has a market capitalization of $5.94 billion, a PE ratio of 60.80 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. This trade represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 757,400 shares of company stock worth $29,343,982 in the last 90 days. Insiders own 17.71% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on HIMS shares. Bank of America upped their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Finally, Piper Sandler increased their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $38.25.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.